[Edaily Reporter Kim Hyung-il ] “Simply possessing good technology is not enough to determine a company’s value. Sustainable growth is only possible by commercializing technology to generate tangible results and establishing a virtuous cycle in which profits generated from business operations are reinvested into research and development (R&D).”

Kim Young-jong, President of Dx & Vx(180400)(Dx & Vx), stated in an interview with E-Daily on the 13th that Dx & Vx plans to translate its technology and business assets into tangible business results and corporate value. The company’s strategy is to maintain its R&D competitiveness centered on diagnostics (DX) and vaccines (VX), while expanding revenue from its diagnostics and healthcare businesses and growing new ventures—such as pharmaceuticals and food—to broaden its revenue base.

President Kim said he intends to grow Dx & Vx into “a cutting-edge bio-food company that serves as a bio-R&D firm specializing in vaccines and diagnostics, while comprehensively evolving into a food and pharmaceutical company based on these foundations.”

China is the first market for expansion. Starting in the second half of this year, the company will expand its existing pharmaceutical business while simultaneously pursuing the localization of its food business. In China, the major shareholder, Cory Group, has operated a pharmaceutical business for about 20 years, establishing a local distribution network and owning food production facilities. Dx & Vx plans to leverage these assets to accelerate the local market entry of its pharmaceutical and food businesses and secure a stable production and distribution base.

The company is also considering overseas expansion with China as a base. Since the Kori Group has established a business presence in the UK, Italy, and the U.S., DXVX plans to leverage these resources to target not only the Chinese market but also Asian markets such as Japan and India, as well as the global market.

In R&D, the focus is on commercializing core technologies. KRNA is a platform that enhances the stability of nucleic acids; it can be applied to nucleic acid-based substances that are difficult to store and distribute at room temperature, and the company is currently validating the technology through Material Transfer Agreements (MTAs) with global companies. ACP is a drug delivery platform that enhances cell permeability, and the company is pursuing its commercialization.

The anticancer vaccine OVM-200 is a therapeutic anticancer vaccine that induces an immune response by targeting survivin, which is expressed in cancer cells; it is currently the most advanced in the clinical stage among Dx & Vx’s new drug pipeline. While preparing for follow-up clinical trials following the UK trial, the company is exploring global commercialization opportunities, including in Asia—such as China and India. The oral GLP-1RA, an oral obesity treatment, is currently in the candidate selection and preclinical development stages.

CEO Kim emphasized the actual adoption of technology over the number of contracts in R&D commercialization. Regarding goals for the next one to two years, he explained, “Our aim is not simply to increase the number of contracts, but to create meaningful success stories where Dx & Vx’s technology is adopted into the development programs of actual global companies.” The plan is to proceed with joint development or licensing based on the results of technology validation.

The company has also left its global commercialization approach open. President Kim stated, “We are keeping all options on the table,” adding, “We are also open to receiving investment.” This means the company intends to accelerate commercialization based on the nature of the technology and the stage of the business, without limiting itself to specific approaches such as joint development, technology transfer, or investment attraction.

In the business division, the company is enhancing the competitiveness of its food, diagnostics, and healthcare businesses, which are already on the market. In the food business, Dx & Vx products are being sold alongside those of other leading pharmaceutical companies in major food retail outlets, thereby expanding distribution channels. The company also noted that health functional foods, such as those for blood circulation and liver health, are receiving a positive response.

In the diagnostics and healthcare sector, new business opportunities are emerging as global pharmaceutical companies request the development of diagnostic methods to screen patients for their medications. While the company aims to boost sales and profitability in its existing businesses based on products currently in development and those already completed, it is also exploring the acquisition of domestic or Asian business rights for diagnostics, vaccines, and pharmaceuticals that have proven competitive overseas.

President Kim has identified next year as the point at which results will become visible. The company’s goal is to use this year to restructure existing businesses and prepare new growth engines, and to begin fully realizing business results—including improved sales and profitability, as well as contracts and partnerships—starting next year.

The company also maintains that it will enhance shareholder value through business performance. It has determined that enhancing the company’s business competitiveness and corporate value takes priority over specific measures such as share buybacks or dividends. President Kim stated that what shareholders ultimately want is “results demonstrated through business performance,” expressing his commitment to returning value to shareholders by strengthening the company’s stability and corporate value.

He also noted that the largest shareholder’s investment of approximately 100 billion won last year serves as evidence of confidence in the company’s technological capabilities and growth potential. President Kim plans to focus his management efforts on creating a virtuous cycle—one that goes beyond merely developing R&D and business operations separately, but rather connects business performance back to the company’s growth engines.